Compile Data Set for Download or QSAR
maximum 50k data
Found 15 Enz. Inhib. hit(s) with all data for entry = 6355
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124184(US8754227, 16)
Affinity DataIC50:  1.40E+3nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124186(US8754227, 18)
Affinity DataIC50:  3.10E+3nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124186(US8754227, 18)
Affinity DataIC50:  3.80E+3nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124184(US8754227, 16)
Affinity DataIC50:  4.10E+3nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124184(US8754227, 16)
Affinity DataIC50:  4.30E+3nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124185(US8754227, 17)
Affinity DataIC50:  5.80E+3nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124186(US8754227, 18)
Affinity DataIC50:  1.10E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124182(US10221160, Example 1 | US11247981, Example 1 | US...)
Affinity DataIC50:  1.60E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124182(US10221160, Example 1 | US11247981, Example 1 | US...)
Affinity DataIC50:  3.50E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124185(US8754227, 17)
Affinity DataIC50:  4.00E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124185(US8754227, 17)
Affinity DataIC50:  4.00E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C19(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 3A4(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124183(US10221160, Example 2 | US11247981, Example 2 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Viamet Pharmaceuticals

US Patent
LigandPNGBDBM124182(US10221160, Example 1 | US11247981, Example 1 | US...)
Affinity DataIC50: >6.00E+4nMAssay Description:Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively...More data for this Ligand-Target Pair
In DepthDetails US Patent